

DAFTAR PUSTAKA

1. Guemas E, Sobanska L, Demar M. *Histoplasma capsulatum* and histoplasmosis: current concept for the diagnosis. In: *Histoplasma and histoplasmosis*. Gulu, IntechOpen; 2020.
2. Mittal J, Ponce M.G, Gendlina I, Nosanchuk J.D. *Histoplasma capsulatum*: mechanisms for pathogenesis. *Curr Trop Microbiol Immunol*. 2019; 422: 157-91
3. Adenis AA, Valdes A, Cropet C, McCotter OZ, Derado G, Couppie P, *et al*. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America. a modelling study *Lancet Infect Dis*. 2018; 18 (10): 1150–9
4. Horwath MC, Fecher RA, Deepe GS. *Histoplasma capsulatum* lung infection and immunity. *Future Microbiol*. 2015; 10 (6): 967–75.
5. Moquet O, Blanchet D, Simon S, Veron V, Michel M, Aznar C. *Histoplasma capsulatum* in Cayenne. French Guiana; *Mycopathologia*: 2012; 174(4): 331-4.
6. Wheat LJ, Azar MM, Loyd JL, Relich RF, Hage CA. *Current concepts in the epidemiology, diagnosis, and management of histoplasmosis syndromes. Seminars in Respiratory and Critical Care Medicine*. 2020; 41(01): 013–030.
7. Ashraf N, Kubat RC, Poplin V, Adenis AA, Denning DW, Wright L, *et al*. Redrawing the maps for endemic mycoses. *Mycopathologia*. 2020; 185(5): 843–65.
8. Pan B, Chen M, Pan W, Liao W. Histoplasmosis: a new endemic fungal infection in China? Review and analysis of cases. *Mycoses*. 2012; 56(3): 212–21.

9. Norkaew T, Ohno H, Sriburee P, Tanabe K, Tharavichitkul P, Takarn P, et al. Detection of environmental sources of *Histoplasma capsulatum* in Chiang Mai, Thailand, by nested PCR. *Mycopathologia*. 2013; 176(5–6): 395–402
10. Azar MM, Malinis MF. Disseminated histoplasmosis with skin lesions and osteomyelitis in a patient from the Philippines. *Am J Trop Med Hyg*. 2016; 95(01): 70–4
11. Randhawa HS, Gugnani HC. Occurrence of histoplasmosis in the Indian sub-continent: an overview and update. *J Med Res Prac*. 2018; 7: 71–83
12. Rangwala F, Putharoen O, Bowonwatanuwong C, Edwards JM, Kramomthong S, Ananworanich J, et al. Histoplasmosis and penicilliosis among HIV-infected Thai patients: a retrospective review. *Southeast Asian J Trop Med Pub Health*. 2012; 43(02): 436–441
13. Wijaya M, Adawiyah R, Wahyuningsih R. Histoplasmosis: diagnostic and therapeutic aspect. *Indo J Trop Infect Dis*. 2021; 9(2): 66.
14. Rozaliyani A, Setianingrum F. The review of histoplasmosis endemicity and current status in Asia. In: Bongomin, F. editor. *Histoplasma and Histoplasmosis*. London: IntechOpen; 2020; 1–15.
15. Araúz AB, Papineni P. Histoplasmosis infectious disease clinics of North America. *Infect Dis Clin North Am*. 2021;35(2): 471-91.
16. Kauffman CA. Histoplasmosis: a clinical and laboratory update. *Clin Micro Rev* 2007; 20(1): 115–32.
17. Fida M, Misra A, Harring JA, Kubbara A, Theel ES. *Histoplasma capsulatum* Complement Fixation and Immunodiffusion Assay Sensitivity in Culture-Confirmed Cases of Histoplasmosis: a 10-Year Retrospective Review (2011 to 2020). *J Clin Microbiol*. 2022;60(10):90.
18. Linder KA, Kauffman CA. Current and new perspectives in the diagnosis of blastomycosis and histoplasmosis. *J Fungi*. 2021; 7(1): 1–10.

19. Valero C, Buitrago MJ, Gago S, Melero QI, Rodriguez GJ. A matrix-assisted laser desorption/ionization time of flight mass spectrometry reference database for the identification of *Histoplasma capsulatum*. *Med Mycol*. 2018; 56: 307–14.
20. Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. *Infect Dis Clin North Am*. 2016; 30(1): 207–27.
21. Kauffman CA. Pulmonary histoplasmosis. *Curr Infec Dis Rep*. 2001; 3(3): 279–285.
22. Taylor ML, del Rocío Reyes-Montes M, Estrada-Bárceñas DA, Zancopé-Oliveira RM, Rodríguez-Arellanes G, Ramírez JA. Considerations about the geographic distribution of histoplasma species. *Appl Environ Microbiol*. 2022; 88(7): 1–11.
23. Powers-Fletcher M V., Kendall BA, Griffin AT, Hanson KE. Filamentous fungi. Hayden RT, Wolk DM, Carroll KC, Tang YW, editors. *Microbiol Spectr*. 2016 May; 4(3): 329–50
24. Limon JJ, Skalski JH, Underhill DM. Commensal fungi in health and disease. *Cell Host Microbe*. 2017 Aug 9; 22(2): 156–65.
25. Jofre GI, Singh A, Mavengere H, Sundar G, D'Agostino E, Chowdhary A, et al. An Indian lineage of *Histoplasma* with strong signatures of differentiation and selection. *Fungal Genet Biol*. 2022 Jan; 158: 103654.
26. Akram SM, Koirala J. Histoplasmosis [Internet]. *StatPearls*. 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28846361>
27. Mruthyunjayappa S LS. *Histoplasma capsulatum* [Internet]. 2022 [cited 2022 Jul 5]. Available from: <https://www.pathologyoutlines.com/topic/microbiologyhcapulatum.html>

28. Baker J, Kosmidis C, Rozaliyani A, Wahyuningsih R, Denning DW. Chronic pulmonary histoplasmosis—a scoping literature review. *Open Forum Infect Dis.* 2020 May 1; 7(5).
29. Sacco M, Medoff G, Lambowitz AM, Kumar BV, Kobayashi GS, Painter A. Sulfhydryl induced respiratory “shunt” pathways and their role in morphogenesis in the fungus *Histoplasma capsulatum*. *J Biol Chem.* 1983; 258(13): 8223–8230
30. Baker J, Setianingrum F, Wahyuningsih, Denning DW. Mapping histoplasmosis in South East Asia – implications for diagnosis in AIDS. *Emerging Microbes & Infections.* 2019; 8(1): 1139–1145.
31. Shen Q, Rappleye CA. Living within the macrophage: dimorphic fungal pathogen intracellular metabolism. *Front Cell Infect Microbiol.* 2020; 10(October): 592259.
32. Wheat LJ, Hage CA. Histoplasmosis. *Diagnosis Treat Fungal Infect.* 2015; 217–24.
33. Bullock WE, Wright SD. Role of the adherence-promoting receptors, CR3, LFA-1 and p150,95, in binding of *Histoplasma capsulatum* by human macrophages. *J Exp Med* 165. 1987; (1): 195–210
34. McDermott AJ, Klein BS. Helper T-cell responses and pulmonary fungal infections. *Immunology.* 2018 Oct; 155(2): 155–63.
35. Garfoot AL, Shen Q, Wüthrich M, Klein BS, Rappleye CA. The *eng1* β -glucanase enhances *Histoplasma* virulence by reducing β -Glucan exposure. Sil A, Berman J, editors. *MBio.* 2016 Apr 19; 7(2): e01388-15.
36. Miller AC, Arakkal AT, Koeneman SH, Cavanaugh JE, Thompson GR, Baddley JW, et al. Frequency and duration of, and risk factors for, diagnostic delays associated with histoplasmosis. *J Fungi.* 2022 Apr 23; 8(5): 438.

37. García-Romero MT. Deep fungal infections. In: Harper's Textbook of Pediatric Dermatology. Wiley; 2019. p. 560–78.
38. Goodwin JR, Owens FT, Snell JD, Hubbard WW, Buchanan RD, Terry RT, Des RP. Chronic pulmonary histoplasmosis. *Medicine (Baltimore)*. 1976; 55: 413-52.
39. Markowitz h. Antibodies in histoplasmosis. *J Bacteriol*. 1967; 93(1): 40-6.
40. Medoff G, Kobayashi GS, Painter A, Travis S. Morphogenesis and pathogenicity of *Histoplasma capsulatum*. *Infect Immun*. 1987; 55(6): 1355–1358
41. Nemecek JC, Wüthrich M, Klein BS. Global control of dimorphism and virulence in fungi. *Science*. 2016; 312(5773): 583–588.
42. Elansari R, Abada R, Rouadi S, Roubal M, Mahtar M. *Histoplasma capsulatum* sinusitis: possible way of revelation to the disseminated form of histoplasmosis in HIV patients: case report and literature review. *Int J Surg Case Rep*. 2016; 24: 97–100.
43. Rizzi MD, Batra PS, Prayson R, Citardi MJ. Nasal histoplasmosis. *Otolaryngol Head Neck Surg*. 2006; 135(5): 803–804.
44. McCormack FX, Gibbons R, Ward SR, Kuzmenko A, Wu H, Deepe GS. Macrophage-independent fungicidal action of the pulmonary collectins. *J Biol Chem*. 2003; 27 (38): 36250–36256.
45. Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore U. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. *Front Immunol*. 2012; 3: 131.
46. Carreto-Binaghi LE, Aliouat eM, Taylor ML. Surfactant proteins, SP-A and SP-D, in respiratory fungal infections: their role in the inflammatory response. *Respir Res*. 2016; 17(1) :66.

47. Van de Wetering JK, van RA, Vaandrager AB, Batenburg JJ, van Golde LM, Hokke CH, *et al* . Surfactant protein D binding to terminal alpha1-3-linked fucose residues and to *Schistosoma mansoni*. *Am J Respir Cell Mol Biol*. 2004; 31(5)
48. Rappleye CA, Engle JT, Goldman WE. RNA interference in *Histoplasma capsulatum* demonstrates a role for alpha-(1,3)-glucan in virulence. *Mol Microbiol*. 2004; 53(1): 153–165.
49. Youseff BH, Holbrook ED, Smolnycki KA, Rappleye CA. Extracellular superoxide dismutase protects *Histoplasma* yeast cells from host-derived oxidative stress. *PLoS Pathog*. 2012; (5): e1002713.
50. Missall TA, Lodge JK, McEwen JE. Mechanisms of resistance to oxidative and nitrosative stress: implications for fungal survival in mammalian hosts. *Eukaryot Cell*. 2004; 3(4): 835–846.
51. Johnson CH, Klotz MG, York JL, Kruft V, McEwen JE. Redundancy, phylogeny and differential expression of *Histoplasma capsulatum* catalases. *Microbiology*. 2002; 148(4): 1129– 1142.
52. Guimarães AJ, Hamilton AJ, de M Guedes HL, Nosanchuk JD, Zancopé-Oliveira RM. Biological function and molecular mapping of M antigen in yeast phase of *Histoplasma capsulatum*. 2018
53. Holbrook ED, Smolnycki KA, Youseff BH, Rappleye CA. Redundant catalases detoxify phagocyte reactive oxygen and facilitate *Histoplasma capsulatum* pathogenesis. *Infect Immun*. 2013; 81(7): 2334–2346.
54. Nittler MP, Hocking-Murray D, Foo CK, Sil A. Identification of *Histoplasma capsulatum* transcripts induced in response to reactive nitrogen species. *Mol Biol Cell*. 2005; 16(10): 4792–4813.

55. Strasser JE, Newman SL, Ciralo GM, Morris RE, Howell ML, Dean GE. Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by *Histoplasma capsulatum*. *J Immunol*. 1999; 162(10): 6148–6154
56. Woods JP. Revisiting old friends: Developments in understanding *Histoplasma capsulatum* pathogenesis. *J Microbiol*. 2016; 54(3): 265–276.
57. Pitangui NeS, Sardi JeC, Voltan AR, Dos Santos CT, da Silva JeF, da Silva RA, *et al*. An intracellular arrangement of *Histoplasma capsulatum* yeast-aggregates generates nuclear damage to the cultured murine alveolar macrophages. *Front Microbiol*. 2015; 6: 1526.
58. Deepe GS, Buesing WR. Deciphering the pathways of death of *Histoplasma capsulatum* infected macrophages: implications for the immunopathogenesis of early infection. *J Immunol*. 2012; 188(1): 334–344.
59. Deepe GS, Gibbons RS, Smulian AG. *Histoplasma capsulatum* manifests preferential invasion of phagocytic subpopulations in murine lungs. *J Leukoc Biol*. 2008; 84(3): 669–678.
60. Thind SK, Taborda CP, Nosanchuk JD. Dendritic cell interactions with *Histoplasma* and *Paracoccidioides*. *Virulence*. 2015; 6(5): 424–432.
61. Sertl K, Takemura T, Tschachler E, Ferrans VJ, Kaliner MA, Shevach EM. Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura. *J Exp Med*. 1986; 163(2): 436–451
62. Holt PG, Schon-Hegrad MA. Localization of T cells, macrophages and dendritic cells in rat respiratory tract tissue: implications for immune function studies. *Immunology*. 1987; 62(3): 349–356
63. Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. *J Invest Dermatology*. 2005; 125(4): 629–637

64. Newman SL, Gootee L, Gabay JE, Selsted ME. Identification of constituents of human neutrophil azurophil granules that mediate fungistasis against *Histoplasma capsulatum*. *Infect Immun*. 2000; 68(10): 5668–5672
65. Cohen NR, Tatituri RV, Rivera A, Watts GF, Kim EY, Chiba A, *et al*. Innate recognition of cell wall β -glucans drives invariant natural killer T cell responses against fungi. *Cell Host Microbe*. 2011; 10(5): 437–450.
66. Zhou P, Freidag BL, Caldwell CC, Seder RA. Perforin is required for primary immunity to *Histoplasma capsulatum*. *J Immunol*. 2001; 166(3): 1968–1974
67. Allen HL, Deepe GS. B cells and CD4-CD8- T cells are key regulators of the severity of reactivation histoplasmosis. *J Immunol*. 2006; 177(3): 1763–1771
68. Guimaraes AJ, Pizzini CV, Almeida MD, *et al*. Evaluation of an enzyme-linked immunosorbent assay using purified, deglycosylated histoplasmin for different clinical manifestations of histoplasmosis. *Microb Res*. 2010;1(1):2.
69. Tristão FS, Leonello PC, Nagashima LA, Sano A, Ono MA, Itano EN. Carbohydrate-rich high-molecular-mass antigens are strongly recognized during experimental *Histoplasma capsulatum* infection. *Rev Soc Bras Med Trop*. 2012; 45(2): 232–237
70. Shi L, Albuquerque PC, Lazar-Molnar E, Wang X, Santambrogio L, Gácsér A, Nosanchuk JD. A monoclonal antibody to *Histoplasma capsulatum* alters the intracellular fate of the fungus in murine macrophages. *Eukaryot Cell*. 2008; 7(7): 1109–1117.
71. Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS, Casadevall A. Antibodies to a cell surface histone-like protein protect against *Histoplasma capsulatum*. *J Clin Investig*. 2003;112 (8):1164–1175.
72. De Freitas RS, Kamikawa CM, Vicentini AP. Fast protocol for the production of *Histoplasma capsulatum* antigens for antibody detection in the

- immunodiagnosis of histoplasmosis. *Revista Iberoamericana de Micología*. 2018; 35(1): 27–31.
73. Azar MM, Hage CA. Clinical Perspectives in the Diagnosis and Management of Histoplasmosis. *Clinics in Chest Medicine*. 2017; 38(3): 403–415.
74. Toscanini MA, Nusblat AD, Cuestas ML. Diagnosis of histoplasmosis: current status and perspectives. *Appl Microbiol Biotechnol*. 2021 Mar 15; 105(5): 1837–59.
75. Guimarães AJ, Nosanchuk JD, Zancopé Oliveira RM. Diagnosis of histoplasmosis. *Braz J Microbiol*. 2006; 37(1): 1–13.
76. Wheat LJ. Improvements in diagnosis of histoplasmosis. *Expert Opin Biolog Ther*. 2006; 6(11): 1207–1221.
77. Richer SM, Smedema ML, Durkin MM, Herman KM, Hage CA, Fuller D, *et al*. Improved diagnosis of acute pulmonary histoplasmosis by combining antigen and antibody detection. *Clin Infect Dis*. 2016; 62(7): 896–902.
78. Denning DW. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. *Philos Trans R Soc B BiolSci*. 2016; 371(1709)
79. Wheat LJ. Histoplasmosis in Indianapolis. *Clin Infect Dis*. 1992; 14(Suppl 1): S91–S99.
80. George RB, Lambert RS. Significance of serum antibodies to *Histoplasma capsulatum* in Endemic areas. *South Med J*. 1984; 77(2): 161–163
81. Picardi JL, Kauffman CA, Schwarz J, Phair JP. Detection of precipitating antibodies to *Histoplasma capsulatum* by counterimmunoelectrophoresis. *Am Rev Respir Dis*. 1976; 114(1) :171– 176.

82. Deppen SA, Massion PP, Blume J, Walker RC, Antic S, et al. Accuracy of a novel histoplasmosis enzyme immunoassay to evaluate suspicious lung nodules. *Cancer Epid Bio and Prev*, cebp.2018.
83. MiraVista sheet about EIA for detection Ig G dan Ig M in histoplasmosis. cited 2023 Feb 14]. available from: <https://miravistalabs.com/medical-fungal-infection-testing/antibody-detection/histoplasma-antibody-igg-igm-eia/>
84. Wheat LJ, Kohler RB, French MLV, Garten M, Kleiman M, Zimmerman SE, et al. Immunoglobulin M and G Histoplasmal Antibody response in histoplasmosis. *American Rev of Resp Dis*. 1983; 128(1): 65–70.
85. GuimarãesAJ, Nosanchuk JD, Zancopé-Oliveira RM. Diagnosis of histoplasmosis. *Braz J Microb*. 2006; 37(1): 1–13.

